Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2018 Feb 15;24(3):661 Authors: Bhandari S, Saeian K, Stein D PMID: 29462393 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29462393?dopt=Abstract

Read More

Nondysplastic Ulcerative Colitis Has High Levels of the Homologous Recombination Repair Protein NUCKS1 and Low Levels of the DNA Damage Marker Gamma-H2AX.

Nondysplastic Ulcerative Colitis Has High Levels of the Homologous Recombination Repair Protein NUCKS1 and Low Levels of the DNA Damage Marker Gamma-H2AX. Inflamm Bowel Dis. 2018 Feb 15;24(3):593-600 Authors: De Angelis PM, Schjølberg AR, Hughes JB, Huitfeldt HS, Norheim Andersen S, Østvold AC Abstract Background: The colon and rectum are continuously exposed to oxidative stress that generates reactive oxygen species, which are a major cause of DNA double-strand breaks (DSB). Furthermore, chronic inflammatory diseases such as ulcerative colitis (UC) are characterized by an excess of reactive nitrogen species that can…

Read More

A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis.

A comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018 Feb 20;: Authors: Hirano A, Umeno J, Okamoto Y, Shibata H, Ogura Y, Moriyama T, Torisu T, Fujioka S, Fuyuno Y, Kawarabayasi Y, Matsumoto T, Kitazono T, Esaki M Abstract BACKGROUND AND AIM: The gut microbiota is suggested to play an important role in the pathogenesis of ulcerative colitis (UC). However, inter-individual and spatial variations hamper the identification of UC-related changes. We thus investigated paired mucosa-associated microbiota obtained from…

Read More

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience.

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501 Authors: Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ Abstract Background: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn’s disease (CD) therapy. Methods: Patients with CD were prospectively evaluated in this large, observational registry. Results: Patients (n = 6273) participated in this observational registry from July 1999 through March 2012; 3440 (54.8%) received infliximab (20,971…

Read More

Combination Immunosuppression in IBD.

Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018 Feb 15;24(3):539-545 Authors: Bots S, Gecse K, Barclay M, D’Haens G Abstract Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last 2 decades. Combination therapy was not superior in any of the registration trials for Crohn’s disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab. It needs to be mentioned, though, that none of these trials were powered to detect such differences, and that many…

Read More

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):465-466 Authors: Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK PMID: 29462402 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29462402?dopt=Abstract

Read More

Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity.

Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity. Inflamm Bowel Dis. 2018 Feb 15;24(3):552-557 Authors: Ewelukwa O, Perez R, Carter LE, Fernandez A, Glover S Abstract Background: Electronic health records (EHRs), despite their positive attributes, increase physician workload and decrease efficiency. The aim of this study was to evaluate the impact of scribes in the Inflammatory Bowel Disease Clinic on improvement of the physician-patient relationship, physician productivity, clinical efficiency, and achievement of some Physician Quality Reporting System (PQRS) metrics. Methods: We analyzed…

Read More

Duodenal Crohn’s Disease.

Duodenal Crohn’s Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):546-551 Authors: Lightner AL Abstract Symptomatic duodenal Crohn’s disease (CD) is an uncommon disease presentation, especially in isolation. The most common duodenal disease phenotype is stricturing disease rather than inflammatory or perforating. Most patients are asymptomatic and are therefore diagnosed incidentally by cross-sectional imaging or endoscopy. Medical management includes proton pump inhibitor therapy and immunosuppressive therapy including corticosteroids, immunomodulatory therapy, and biologic therapy. Symptomatic strictures can often be treated medically or endoscopically, and do not always require surgery. Surgical options include resection…

Read More
<< Go Back